1432055-36-1

Basic information

• Product Name: tert-butyl 4-(5-chloro-6-methoxypyridin-3-yl)-3-methylbenzoate
• Synonyms: tert-butyl 4-(5-chloro-6-methoxypyridin-3-yl)-3-methylbenzoate
• CAS NO: 1432055-36-1
• Molecular Weight: 333.815
• Mol File: 1432055-36-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(5-chloro-6-methoxypyridin-3-yl)-3-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(5-chloro-6-methoxypyridin-3-yl)-3-methylbenzoate(1432055-36-1)
• EPA Substance Registry System: tert-butyl 4-(5-chloro-6-methoxypyridin-3-yl)-3-methylbenzoate(1432055-36-1)

Safety Data

• Hazardous Substances Data: 1432055-36-1(Hazardous Substances Data)

Upstream product

• 1073493-92-1 tert-butyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 848366-28-9 5-bromo-3-chloro-2-methoxypyridine 
• 347174-28-1 tert-butyl 4-bromo-3-methylbenzoate 
• 7697-28-1 4-bromo-3-methylbenzoic acid 

Downstream Products

• 1432055-59-8 tert-butyl 4-{5-[2-{(1R,5S,7aS)-1-[3,5-bis(trifluoromethyl)phenyl]-3-oxotetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-5-yl}-4-(trifluoromethyl)phenyl]-6-methoxypyridin-3-yl}-3-methylbenzoate 
• 1432054-03-9 4-{5-[2-{(1R,5S,7aS)-1-[3,5-bis(trifluoromethyl)phenyl]-3-oxotetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-5-yl}-4-(trifluoromethyl)phenyl]-6-methoxypyridin-3-yl}-3-methylbenzoic acid 
• 1432055-38-3 tert-butyl 4-[6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]-3-methylbenzoate 

Relevant articles and documents

Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties ()

Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased HDL and decreased LDL to coronary heart disease (CHD) risk reduction. This relationship is consistent with a clinical outcomes trial of a CETP inhibitor (anacetrapib) combined with standard of care (statin), which led to a 9% additional risk reduction compared to standard of care alone. We discuss here the discovery of MK-8262, a CETP inhibitor with the potential for being the best-in-class molecule. Novel in vitro and in vivo paradigms were integrated to drug discovery to guide optimization informed by a critical understanding of key clinical adverse effect profiles. We present preclinical and clinical evidence of MK-8262 safety and efficacy by means of HDL increase and LDL reduction as biomarkers for reduced CHD risk.

SPIROCYCLIC CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing at

LONG INTERFERING DSRNA SIMULTANEOUSLY INDUCING AN IMMUNE REACTION AND THE INHIBITION OF THE EXPRESSION OF TARGET GENES

The present invention relates to a long interfering dsRNA (liRNA) capable of promoting an immune reaction as well as inhibiting the expression of specific RNAi-mediated target genes, and to uses thereof. More particularly, the present invention relates to